Barclays PLC Buys 33,494 Shares of Apogee Therapeutics Inc. $APGE

Barclays PLC boosted its stake in shares of Apogee Therapeutics Inc. (NASDAQ:APGE) by 5.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 642,316 shares of the company’s stock after purchasing an additional 33,494 shares during the quarter. Barclays PLC owned 1.39% of Apogee Therapeutics worth $25,519,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of APGE. ANTIPODES PARTNERS Ltd lifted its stake in shares of Apogee Therapeutics by 41.2% in the third quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock valued at $33,000 after buying an additional 246 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Apogee Therapeutics by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock valued at $921,000 after acquiring an additional 694 shares during the period. BNP Paribas Financial Markets raised its holdings in Apogee Therapeutics by 34.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,649 shares of the company’s stock valued at $158,000 after acquiring an additional 941 shares in the last quarter. Handelsbanken Fonder AB raised its holdings in Apogee Therapeutics by 13.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 8,500 shares of the company’s stock valued at $369,000 after acquiring an additional 1,000 shares in the last quarter. Finally, HighVista Strategies LLC lifted its position in shares of Apogee Therapeutics by 4.3% in the 2nd quarter. HighVista Strategies LLC now owns 45,052 shares of the company’s stock worth $1,957,000 after acquiring an additional 1,862 shares during the period. 79.04% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $71.06, for a total value of $390,830.00. Following the completion of the transaction, the insider directly owned 209,773 shares of the company’s stock, valued at $14,906,469.38. The trade was a 2.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael Thomas Henderson sold 20,000 shares of the company’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $63.35, for a total transaction of $1,267,000.00. Following the transaction, the chief executive officer owned 1,172,987 shares in the company, valued at approximately $74,308,726.45. This trade represents a 1.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 1,819,700 shares of company stock worth $138,622,483. 42.77% of the stock is owned by corporate insiders.

Apogee Therapeutics Price Performance

NASDAQ APGE opened at $74.68 on Thursday. The stock’s 50 day simple moving average is $72.33 and its 200 day simple moving average is $61.63. Apogee Therapeutics Inc. has a one year low of $26.20 and a one year high of $84.56. The firm has a market cap of $5.19 billion, a PE ratio of -17.70 and a beta of 1.39.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.02. As a group, equities analysts expect that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on APGE shares. Wolfe Research started coverage on Apogee Therapeutics in a report on Wednesday, January 7th. They set a “peer perform” rating on the stock. Deutsche Bank Aktiengesellschaft began coverage on Apogee Therapeutics in a research report on Tuesday, December 9th. They issued a “buy” rating and a $103.00 target price for the company. Stephens began coverage on shares of Apogee Therapeutics in a research note on Tuesday, December 16th. They set an “overweight” rating and a $95.00 price target on the stock. Stifel Nicolaus set a $133.00 price target on shares of Apogee Therapeutics in a report on Tuesday, January 6th. Finally, UBS Group upgraded shares of Apogee Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 7th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.92.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.